An award-winning journalist, Derrick has written extensively about user fee negotiations, the FDA budget, FDA travel restrictions and drug advertising compliance. He also was part of the Pink Sheet team covering FDA's first biosimilar advisory committee meetings.
When he's not following FDA, Derrick is keeping close tabs on Indiana Hoosiers basketball.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Derrick Gingery
Suggested cuts to appropriations bill funding government for remainder of fiscal year 2017 also includes 'administrative savings.'
CDER's Woodcock suggests exclusivity rules outdated for abuse-deterrent technology development, and Rep. Griffith takes it to mean legal changes are needed.
Sen. Burr asks FDA whether fee revenue should be rebated for not meeting some PDUFA V goals.
When asked about the effect of Trump's potential cuts to FDA, agency officials are not allowed to discuss it, creating more uncertainty about the budget and user fee process.
US FDA commissioner nominee might employ modular specialists to work with review divisions on issues related to gene therapies, molecularly-targeted drugs, adaptive clinical trial designs, or other complex issues.
White House allowed agency to hire some new employees, but lawmakers remain concerned about federal hiring freeze's effect on FDA.